Advisory - One lot of GENIUS Kids and Teens softgel capsules recalled due to possible bacterial contamination
OTTAWA, ON, Oct. 6, 2021 /CNW Telbec/ -
Summary
Product: GENIUS Kids and Teens natural health product (softgel capsules)
Issue: Nutripur Inc. is recalling one lot (lot GC2210-1, expiry 08-23) due to possible bacterial contamination with Staphylococcus aureus, which may pose serious health risks. Children, teens and people with weakened immune systems may be more vulnerable to these risks.
What to do: Stop using the recalled product. Consult a health care professional if you have used the product and have health concerns.
Issue Nutripur Inc. is recalling one lot (lot GC2210-1, expiry 08-23) of GENIUS Kids and Teens softgel capsules due to possible bacterial contamination with Staphylococcus aureus, which may pose serious health risks.
The natural health product is advertised for use in children and teenagers to help support brain and eye health, concentration and mental function, and the management of attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD).
Ingesting the contaminated product may result in symptoms including abdominal discomfort or pain, diarrhea, nausea and vomiting. Children, teens and people with weakened immune systems may be more vulnerable to these adverse effects.
The products were distributed starting August 2021.
Health Canada is monitoring the recall. If additional safety information is identified, Health Canada will take appropriate action to inform Canadians.
Affected products
Product Name
NPN
Lot #
Expiry
GENIUS Kids and Teens softgel capsules
80001375
GC2210-1
08-23
What you should do
Stop using the recalled product. Consult a health care professional if you or your child have used the product and have health concerns.
Contact Nutripur Inc. at 1-450-435-2040 or by emailing [email protected] if you have questions about the recall.
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...